Abstract
Introduction
Stroke is the major cause of mortality among the elderly population and a common cause of long-term disability worldwide. Furthermore, the stroke burden continues to increase, especially in developing countries such as China [1, 2] . Ischemic stroke (IS) is a major type of stroke defined as a cerebrovascular accident caused by occlusion of the cerebral arteries leading to sudden neurologic deficit, such as loss of motor function, altered sensations, and cognition or language impairments [3] . Increasing evidence has revealed that both environmental [4] [5] [6] and genetic factors might contribute to the occurrence of IS [7] .
Methylene tetrahydrofolate reductase (MTHFR) is a key enzyme in the metabolism of circulating homocysteine (tHcy) [8] , which is in turn a crucial intermediate in methionine metabolism and causes excessive production of reactive oxygen species (ROS) [9, 10] . tHcy accumulation can elevate ROS levels by activating MAPK signaling, resulting in cell apoptosis [11] . tHcy has been identified as a risk factor for IS, and is thought to increase thrombotic risk by inducing endothelial injury in the venous and arterial vasculature [12, 13] . Functional polymorphisms in the exon region of the MTHFR have been shown to be associated with the pathogenesis of IS. For example, the rs1801133 polymorphism was associated with reductions in MTHFR activity of approximately 70% and 35% in TT and CT genotype carriers, respectively, leading to increased levels of tHcy, which predicted a poor prognosis among IS patients [14] [15] [16] . The A1298C variant resulted in substitution of glutamate (Glu) by alanine (Ala) at codon 429 in the S-adenosylmethionine regulatory domain of the MTHFR protein [17] [18] [19] .
Traditional analyses of genetic polymorphisms in IS patients have focused on genotype frequencies in patients and control samples. However, micro RNAs (miRNAs) have been shown to function in single nucleotide polymorphisms (SNP)-associated post-transcriptional regulation, and the binding of certain miRNAs could be influenced by different genotypes, resulting in different mRNA expression levels. These functional miRNAs have been reported to play crucial roles in the development and prognosis of human diseases. In this study, we aimed to validate the MTHFR rs142884651 SNP previously screened in a genome-wide association study (GWAS) by our group (data not published). The potential interaction between this polymorphism and miRNA was predicted by multiple bioinformatics analysis.
Materials and Methods
Clinical information 400 patients diagnosed with ischemic stroke between July 2010 and October 2016 were enrolled. Diagnosis of patients with ischemic stroke was established clinically and confirmed by using X-ray computed tomography and/or magnetic resonance imaging scans of the brain. The subtype of stroke patients in this study was all the patients with large vessel disease. Another 400 sample collected from healthy control were regarded as control group from this hospital during the same period of time and they were matched to the cases by age and gender. All control individuals visited our hospital for annual health check-ups and were free of ischemic stroke. Diabetes mellitus was defined as a fasting glucose level ≥ 7.0 mmol/L and/ or ≥ 11.1 mmol/L 2 h after oral glucose challenge, or receiving anti-diabetic medication. Subjects who had smoked more than 10 cigarettes daily for 5 years were considered as smokers. Subjects who drank more than 50 ml of alcoholic beverages daily for 5 years were considered as alcohol drinkers. The National Institutes of Health Stroke Scale (NIHSS) score was used to quantify stroke severity in patients at the time of presentation and discharge. This study was approved by the Ethics Committee of Kunshan Rehabilitation Hospital and The Sixth People's Hospital of Nantong and the study was conducted in accordance with the Helsinki Declaration.
Genotyping
Blood samples were collected after a 12 h overnight fasting period and then separated into serum, red blood cells, and buffy coat. Genomic DNA from peripheral whole blood of every validation subject was extracted by using QIAamp DNA blood mini kits (Qiagen, Hilden, Germany) according to the manufacturer's instructions. After quantification, these DNA samples were subjected to DNA genotyping using the TaqMan SNP Genotyping Assay. Briefly, genomic DNA samples of 10 ng each were amplified using PCR in a total volume of 5 μL containing TaqMan Universal Master Mix, 80x SNP Genotyping AssayMix, DNase-free water C for 1 min in a 384-well ABI 7900HT Real Time PCR System as described previously [20] .
Bioinformatic analysis of miRNAs binding to MTHFR SNP
Bioinformatics software (http://www.bioguo.org/miRNASNP/ and http://bioinfo.life.hust.edu.cn/ miRNASNP2/index.php) was used to detect the candidate SNPs which could affect MTHFR gene regulation via miRNAs.
Cell line, culture, transfection and luciferase reporter assay
Embryonic Kidney 293T cells were obtained from the Chinese Academy of Sciences Cell Bank (Shanghai, China) and cultured in RPMI-1640 (Gibco, Gaithersburg, MD, USA) supplemented with 10 % fetal bovine serum (Invitrogen, Carlsbad, CA, USA) in a humidified incubator with 5 % CO 2 at 37 o C. The mimics and control were obtained from Genepharma (Shanghai, China) and transfected into 293T cells by using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol.
MTHFR 3'-UTR fragments containing either G or A alleles were amplified using PCR from genomic DNA and cloned into pGL3-promoterless luciferase-based plasmids (Promega, Madison, WI, USA) multiple cloning sites. MTHFR 3'-UTR fragments potentially binding to miRNAs, predicted by bioinformatics analysis or a mutated sequence with the predicted target sites, were cloned using PCR from genomic DNA and inserted into the pGL3 promoter vector (Genscript, Nanjing, China). The cloned plasmids were amplified and verified by DNA sequencing.
For the dual-luciferase reporter assay, 293T cells were plated onto 24-well plates and transfected with 100 ng of pGL3-MTHFR wild, pGL3-MTHFR mutant, and miRNA mimics, respectively, using Lipofectamine 2000 (Invitrogen). A Renilla luciferase vector pRL-SV40 (5 ng) was also co-transfected as a normalization and transfection efficiency control. Each experiment was performed in triplicate and luciferase activity was assessed 48 h after transfection using the dual-luciferase reporter assay system (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity according to a previous study [21] .
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
The qRT-PCR was performed to determine levels of MTHFR mRNA. In brief, total RNA was isolated from 293T cells using a Trizol reagent (Invitrogen, Carlsbad, CA, USA) and reverse transcribed into cDNA using the TaqMan ® Reverse Transcription Kit, according to the manufacturers' instructions (ABI, CA, USA). The cDNA samples were then subjected to qPCR amplification under conditions of 95 °C for 10 min followed by 40 cycles of 95 °C for 30 s, 55 °C for 40 s, and 72 °C for 30 s, and finally 4 °C for 30 min using the Realmaster Mix (SYBR Green I) (TAKARA, Dalian, China).
ELISA of plasma homocysteine levels
Plasma levels of tHcy in patients was assessed using a tHcy ELISA kit (Green Stone, Bern, Switzerland), according to the manufacturers' protocol. The level of plasma tHcy was normalized to the kit standard and the data were summarized as Mean ± SD and then associated with outcome in ischemic stroke patients.
Statistical analysis
The association between different genetic variants and ischemic stroke risk was evaluated by calculation of the odds ratios (ORs) and 95% confidence intervals (CIs) using univariate and multivariate logistic regression analysis. The difference in association of MTHFR mRNA levels with three MTHFR genotypes and of the relative luciferase activity between the wild and mutant genotype were evaluated by using an independent-sample t test. The chi-square test was applied to analyze the difference between clinical characteristics of ischemic stroke patients and healthy controls. Data normality of distribution was calculated by confirming coefficient of skewness and coefficient of kurtosis with 0 and Kolmogorov-Smirnov test with the P>0.05. A goodness-of-fit c2-test was performed to estimate Hardy-Weinberg equilibrium of the genotype distribution among control subjects for evaluating possible selection bias and genotyping errors. For the clinical outcome correlation of rs142884651 genotype with IS patients, multigroup comparisons were carried out by one-way analysis of variance (ANOVA) test with post hoc contrasts by Student-Newman-Keuls test. All statistical analyses were two-sided and P<0.05 was considered statistically significant using SPSS
Results

Clinical characteristics
There was no significant difference in the distribution of patient age or gender between the IS and healthy controls ( Table  1 ). The common risk factors for IS, including smoking, drinking, diabetes, and hypertension were more common in the IS compared with the control group (P < 0.001). In addition, the traditional biomarkers for cardiovascular and cerebrovascular diseases, including total cholesterol, HDL-C, and LDL-C, were also associated with the occurrence of IS.
MTHFR rs142884651 polymorphism protects against IS
The rs142884651 polymorphism located in the 3′ UTR of the MTHFR gene was screened by GWAS (data not published). We aimed to validate the distribution of MTHFR genotypes among IS patients in this case-control group. The distribution of the rs142884651 polymorphism differed between the 400 IS patients and the control group (Table  2) . Logistic regression analysis revealed that MTHFR rs142884651 GA and AA genotypes were significantly associated with decreased risks of developing IS compared with the GG genotype (OR: 0.68; 95% CI: 0.22-0.87 for GA genotype, and OR: 0.45; 95% CI: 0.29-0.58 for AA genotype; Table 2 ). A higher number of A alleles was also associated with a decreased risk of IS (OR: 0.57; 95% CI: 0.29-0.69). Table 2 . Genotype frequencies of the MTHFR rs142884651 in IS patients and healthy controls. a The ORs, 95% CIs and P value were calculated after adjusting for age, gender, smoking, drinking and other characteristics listed in Table1 MTHFR expression levels were decreased in patients harboring the A allele, indicating that this SNP located in the 3′ UTR of MTHFR effect its expression (P = 0.023) (Fig. 1A) . We therefore performed bioinformatics analysis to determine if MTHFR rs142884651 could interact with miRNAs. Eleven candidate miRNAs were identified by expression correlation values using prediction software (Table 3 ). We cloned these 11 candidate miRNA mimics and transfected them into either MTHFR wild-type or mutant cells. We confirmed binding by luciferase assay and found that the luciferase activity of the G-allele-specific pGL3 construct was significantly suppressed by let-7f and miR-196a (P = 0.021 and 0.019, respectively) ( Fig. 1B and C) .
MTHFR rs142884651 polymorphism predicts a better outcome in IS patients
Given that increased MTHFR could promote the metabolism of tHcy, potentially leading to a better prognosis in IS patients, we assessed the association between MTHFR rs142884651 and short-term IS outcome. Initial stroke severity in the acute phase, measured by the NIHSS, differed significantly among the different genotypes. Recovery from IS was measured as the change in NIHSS score from the acute phase to 3 months post-stroke, with a negative value indicating a clinical improvement in IS outcome. The rs142884651 polymorphism predicted a better outcome in IS patients. We also detected levels of MTHFR mRNA expression and circulating tHcy and found that patients with a GA or AA genotype had higher MTHFR expression and decreased levels of tHcy (Table 4) .
Discussion
MTHFR is an important enzyme involved in ROS signaling, especially in relation to tHcy degradation [22] . Indeed, ROS generation is enhanced under ischemic conditions, potentially causing damage to various types of cells, including brain endothelial cells, leading to formation of thromboses and loss of brain function [23] . The current study provided direct evidence to show that the novel MTHFR rs142884651 polymorphism decreased the risk of IS compared with healthy controls. Mechanistically, MTHFR rs142884651 altered the binding of let-7f and miR-196a to negatively regulate MTHFR expression, thus providing a post-transcriptional mechanism for gene regulation and expression. Increased ROS generation can lead to damage of various types of cells, including brain endothelial cells, causing thrombosis and loss of brain function [24] . MTHFR is an important enzyme in ROS signaling, especially in terms of the degradation of tHcy [22] . Genetic studies have so far revealed more than 40 point mutations in the MTHFR gene, of which C677T (rs1801133) and A1298C (rs1801131) appear to have the most clinical significance. The MTHFR rs1801133 polymorphism involves a C to T substitution at position 677 (C677T) resulting in the conversion of alanine to valine [24] . This missense mutation results in reductions in MTHFR activity of approximately 70% and 35% in TT and CT genotype carriers, respectively, compared with wild-type MTHFR. MTHFR activity has an adverse effect on tHcy levels. The 677TT allele was also associated with elevated tHcy levels, predominantly in individuals with low plasma folate levels. Higher tHcy concentrations have in turn been shown to have a negative effect on stroke [16, 19] .
Accumulating evidence suggests that SNPs localized at miRNA-binding sites may affect the binding of miRNAs to their target genes, leading in turn to reduced or increased translation of the target mRNA and altered susceptibility to cancer. For example, the rs2910164 polymorphism harboring the sequence for miR-146a was shown to influence susceptibility to gastric cancer in a Chinese population, while rs4143815 and rs4819388 SNPs in the 3'-UTRs of B7-H1 and B7-H2 genes, respectively, were also associated with the development of gastric cancer [25] . The function of SNPs localized at miRNA-binding sites, also defined as 3′ UTRs, could affect the binding of miRNAs to their targets and thereby suppress or activate the expression of the target genes and alter the susceptibility to cancer [20, 26] . In addition, our results showed that MTHFR rs142884651 SNP could affect let-7f and miR-196a binding, leading to low cellular MTHFR This study had some limitations. We did not further assess the effects of the miRNAs on the regulation of IS risk and outcome. In addition, our study was conducted in a West Chinese Han population, and may also have been affected by type 1 statistical errors. The results should therefore be confirmed in independent samples or samples from another ethnic population, and should also be verified in future studies with larger sample sizes.
Conclusion
In summary, we demonstrated that the MTHFR rs142884651 SNP is associated with a decreased risk of IS and may act as a biomarker of short-term outcome in IS patients.
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